Table 3 Comparison of baseline patients’ characteristics based on patients with baseline absolute lymphocyte counts
Characteristics | Absolute lymphocyte counts | P value | |
|---|---|---|---|
≥ 1500/μL (n = 19) | < 1500/μL (n = 32) | ||
Median age (range) | 58 (32–76) yo | 58 (31–77) yo | 0.7109 |
Estrogen receptor | |||
Positive | 8 (42%) | 15 (47%) | 0.7787 |
Negative | 11 (58%) | 17 (53%) | |
Progesterone receptor | |||
Positive | 4 (21%) | 7 (22%) | 1.0000 |
Negative | 15 (79%) | 25 (78%) | |
HER2 | |||
3+ | 12 (63%) | 28 (88%) | 0.0754 |
2+ FISH amplification | 7 (37%) | 4 (12%) | |
Visceral metastases | 5 (26%) | 14 (47%) | 0.2465 |
Non-visceral metastases | 14 (74%) | 18 (56%) | |
Prior treatment | |||
< 3 lines | 13 (68%) | 17 (53%) | 0.3808 |
≥ 3 lines | 6 (32%) | 15 (47%) | |
Combination chemotherapy with trastuzumab plus pertuzumab | |||
Eribulin | 8 (42%) | 22 (69%) | 0.0815 |
Nab-paclitaxel | 11 (58%) | 10 (31%) | |